Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10259035 | 0.80 | POLB (0.34) | POLBRAB9ARXFP1KDM4EALDH1A1 | |
| SCHEMBL20910327 | 0.79 | POLB (0.33) | POLBRAB9ARXFP1KDM4EALDH1A1 | |
| SCHEMBL520454 | 0.77 | JAK2 (0.45) | ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL10258799 | 0.76 | TP53 (0.31) | KDM4E | |
| SCHEMBL25327119 | 0.75 | KDM4E (0.32) | POLBRAB9ARXFP1KDM4E | |
| SCHEMBL18078323 | 0.75 | KDM4E (0.37) | POLBRAB9ARXFP1KDM4E | |
| SCHEMBL520320 | 0.75 | KDM4E (0.33) | POLBRAB9ARXFP1KDM4EALDH1A1 | |
| SCHEMBL19876452 | 0.73 | KDM4E (0.43) | POLBRAB9ARXFP1KDM4EALDH1A1 | |
| SCHEMBL521646 | 0.73 | JAK2 (0.38) | POLBRAB9ARXFP1KDM4EALDH1A1 | |
| SCHEMBL519714 | 0.73 | KDM4E (0.52) | POLBRAB9ARXFP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655302-A1 | TYRO3 SELECTIVE INHIBITORS AND USES THEREOF | The University of North Carolina at Chapel Hill (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | KHORA SPV 1, LLC | 2025-05-22 | — | — | US | disclosed |
| EP-4469062-A1 | INHIBITORS OF CDK4/6 KINASE | Kinnate Biopharma Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-119013030-A | Inhibitors of CDK4/6 kinase | 金耐特生物制药公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024159097-A1 | TYRO3 SELECTIVE INHIBITORS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2023147372-A1 | INHIBITORS OF CDK4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147372-A1 | INHIBITORS OF CDK4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230212174-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF | TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212174-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF | TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| WO-2022257732-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES AND APPLICATION THEREOF | 腾讯科技（深圳）有限公司 | 2022-12-15 | — | — | WO | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212174-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF | CYP11B2, CYP11B1, CYP4F11 | POLB 834/4885RAB9A 3705/4885RXFP1 1752/4885 |
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | CDK4, CDK6, CDK2 | POLB 639/4885RAB9A 2766/4885RXFP1 4618/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | POLB 860/4885RAB9A 3888/4885RXFP1 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.